Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger
- PMID: 28228112
- PMCID: PMC5322655
- DOI: 10.1186/s12887-017-0813-0
Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger
Abstract
Background: Bullous pemphigoid (BP) is a blistering skin disorder infrequent in infancy and rarely reported in medical literature.
Case presentation: Here we describe three cases of BP which were referred to our department in the last 15 years. Two of them developed an eruption of bullous lesions just a few days after vaccination for diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B. The third patient developed the same blistering lesions shortly after herpetic stomatitis. In all three cases, clinical diagnosis was confirmed by histological examination which showed subepidermal bullae with a dermal inflammatory infiltrate, and direct immunofluorescence of perilesional skin showed linear IgG and C3 deposits along the basement membrane zone. Immunoblot assay was positive for BP antigen 180. Treatment with oral prednisone was instituted and the lesions resolved in two out of three patients; the third one was treated with an immunosuppressive agent (tacrolimus) and corticosteroid and subsequently with intravenous immunoglobulin and plasmapheresis, due to an underlying complex autoimmune disease.
Conclusion: Although the mechanism of induction of BP is still unclear, the close relationship between trigger events (immunization or viral infection) and onset of the disease arises a possible association.
Keywords: Bullous Pemphigoid; Case report; Drug therapy; Infant; Vaccination.
Figures



Similar articles
-
Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.Acta Dermatovenerol Croat. 2017 Oct;25(3):255-256. Acta Dermatovenerol Croat. 2017. PMID: 29252183
-
Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.G Ital Dermatol Venereol. 2008 Feb;143(1):1-8. G Ital Dermatol Venereol. 2008. PMID: 18833046 Clinical Trial.
-
Childhood bullous pemphigoid treated by i.v. immunoglobulin.J Dermatol. 2007 Sep;34(9):650-3. doi: 10.1111/j.1346-8138.2007.00348.x. J Dermatol. 2007. PMID: 17727369
-
Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review.Pediatr Dermatol. 2013 Nov-Dec;30(6):741-4. doi: 10.1111/pde.12231. Epub 2013 Oct 11. Pediatr Dermatol. 2013. PMID: 24125034 Review.
-
Two cases of subepidermal blistering disease with anti-p200 or 180-kD bullous pemphigoid antigen associated with psoriasis.Dermatology. 2004;209(2):149-55. doi: 10.1159/000079602. Dermatology. 2004. PMID: 15316172 Review.
Cited by
-
A Systematic Review of Drug-Induced Pemphigoid.Acta Derm Venereol. 2020 Aug 17;100(15):adv00224. doi: 10.2340/00015555-3457. Acta Derm Venereol. 2020. PMID: 32176310 Free PMC article.
-
Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin.Front Immunol. 2019 May 14;10:1089. doi: 10.3389/fimmu.2019.01089. eCollection 2019. Front Immunol. 2019. PMID: 31156638 Free PMC article. Review.
-
Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.JAMA Dermatol. 2024 Dec 1;160(12):1278-1287. doi: 10.1001/jamadermatol.2024.4233. JAMA Dermatol. 2024. PMID: 39504045
-
Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine.Ann Dermatol Venereol. 2022 Mar;149(1):56-57. doi: 10.1016/j.annder.2021.07.008. Epub 2021 Sep 30. Ann Dermatol Venereol. 2022. PMID: 34686374 Free PMC article. No abstract available.
-
BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.Front Immunol. 2017 Dec 8;8:1752. doi: 10.3389/fimmu.2017.01752. eCollection 2017. Front Immunol. 2017. PMID: 29276517 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous